Compare DAKT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | JANX |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 790.3M |
| IPO Year | 1996 | 2021 |
| Metric | DAKT | JANX |
|---|---|---|
| Price | $20.13 | $13.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.60 |
| AVG Volume (30 Days) | 602.4K | ★ 784.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | $10,000,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $7.35 | $209.90 |
| P/E Ratio | $28.07 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $10.95 | $12.12 |
| 52 Week High | $28.27 | $35.34 |
| Indicator | DAKT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 46.12 |
| Support Level | $18.53 | $13.01 |
| Resistance Level | $20.50 | $13.79 |
| Average True Range (ATR) | 1.12 | 0.55 |
| MACD | -0.75 | 0.07 |
| Stochastic Oscillator | 0.59 | 37.58 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.